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Objective: To measure the effect of intensive therapy and 
the lasting effect of a standardized functional training pro-
gramme with vs. without the addition of chemodernervation 
of the muscles of the forearm and hand. 
Patients and methods: Twenty children with spastic hemiple-
gia, aged 4–16 years, were matched for baseline characteris-
tics and randomized to standardized task-oriented therapy 
for 6 months with or without botulinum toxin injections. 
Dynamic kinematic outcome measures were: speed, accu-
racy, end-point spread and performance. Measurements of 
active and passive range of motion, stretch-restricted angle 
of the elbow and wrist, Ashworth scores and Melbourne As-
sessment of Unilateral Upper Limb Function were made. All 
measures were performed at baseline, 2 weeks after injec-
tion of botulinum toxin and after 6 months (at the end of 
therapy), and 3 months after end of the therapy. 
Results: Clinical measures showed improvement in both 
groups. However, no significant differences emerged between 
groups on functional measures. Directly after the botulinum 
toxin injection all kinematic outcome measures showed a 
decrease, but baseline values were re-established during the 
therapy period. After botulinum toxin injections a tempo-
rarily significant greater increase in speed and performance 
was found. These results illustrate the need for further quan-
titative research into the effects of botulinum toxin.
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INTRODUCTION
Children with spastic hemiplegia encounter many problems in 
performing manual tasks (1). Research in the last decade has 
lead to a better picture of the movement characteristics of the 
affected upper limb (2–5). Compared with typically developing 
children, children with spastic hemiplegia have slower upper 
limb movements, and an increased number of sub-movements, 
combined with excessive trunk movements (2–5). Furthermore, 
they also have decreased scores in manual performance tests, 
such as the Jebsen Taylor test (6), Melbourne Assessment of 
Unilateral Upper Limb (MA) (7) and Quality of Upper Extrem-
ity Skills Test (QUEST) (8, 9). 
An important question arises; namely, what are the underly-
ing causes of this deficit?
The primary motor cortex is crucially involved in execution 
of movement of the fingers and is often damaged in hemiparesis 
(10). This most often results in spasticity and pareses (11–14). 
If spasticity is the major factor eliciting such impairments then 
2 questions are important; whether spasticity can be decreased 
by intervention and, if so, whether this will lead to positive 
changes in hand function. 
A common intervention used to treat spasticity is injec-
tions with botulinum toxin-A (BoNT-A) (15). BoNT-A has 
a paralysing effect on the injected muscles and blocks the 
release of acetylcholine in the synapses of the motor units for 
the coordination of the muscles. BoNT-A decreases spasticity 
and muscle strength in the injected muscles and increases the 
active range of motion of the antagonists (15–17). Current 
evidence does not allow any conclusion to be drawn about 
the positive or negative effect of BoNT-A on manual function 
(18–21). This lack of consistency illustrates the need for more 
rigorous quantitative tasks (19–21). 
Using isometric wrist flexor force tasks we have shown that 
the wrist flexor force decreased immediately after BoNT-A 
injection and increased slightly at the end of therapy (22).
It may be argued that some of these quantitative tests do not 
sufficiently represent activities of daily living (ADL). There-
fore, in parallel, we used a kinematic aiming task (KAT) as a 
quantitative and reliable way to assess changes in arm move-
ments. It was found that, directly after BoNT-A injection, the 
accuracy and speed of movements in such aiming tasks were 
reduced (16).
A first rationale for the current study was to expand these 
tasks so as to mimic more closely the activities normally per-
formed by these children. Three different kinematic aiming 
tasks were developed; a discrete lift task, a discrete shift task 
and an alternating shift task. All 3 tasks represent different 
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aspects of movements occurring in ADL, such as writing, 
lifting a small object and placing an object. 
In the discrete lift and shift tasks the movements have to be 
made with start and stop signals for each movement. These 
tasks are chosen to test the ability to accelerate and slow down 
the object, guided by visual information, which is essential in 
order to carry out these tasks accurately (23). Compared with 
the shift tasks, the load on muscle strength in proximal arm 
muscles in the lift task is higher, because the whole arm has 
to be lifted from the surface. In the alternating task fast move-
ments had to be made between 2 targets. Controlled activation 
and release of agonist and antagonist muscles are required to 
perform this task well (4, 5, 23). 
For evaluation purposes it is obligatory that the data from 
kinematic recordings have small measurement error in order 
to be able to detect change over time (16). Such objective 
and clinical essential data are provided by parameters such as 
accuracy and movement speed. Both are important elements 
determining the performance in a goal-directed task. This speed 
accuracy trade-off is expressed in a mathematical relationship 
in Fitts Law (24). Importantly, Fitts Law can be used to equate 
the performance of the motor system by combining the speed 
and accuracy in a single outcome measure, the Index of Per-
formance Effective (IP-E) (3).
The present study examined the effect of standardized 
therapy (PT/OT) and BoNT-A on the changes in accuracy and 
movement speed. 
After BoNT-A injection, it is assumed that muscle tone and 
co-contraction decreased (15). If so, this may allow faster 
movement towards an object. This effect is predicted to be most 
obvious in the alternating aiming tasks, because such tasks have 
a robust advantage in speed accuracy trade-off over discrete 
tasks. Smits Engelsman et al. (3) found that movement speed 
was higher in cyclical alternating movements. This was based 
on incorporated stretch-shortening cycles. The muscles can 
generate more force after stretch and benefit from the energy 
stored in the elastic tissue, which is released during muscle 
shortening. This will enable movement with greater speed (3). 
In contrast, a discrete aiming task may have an advantage with 
respect to accuracy because attention can be focused on the 
homing-in phase, when the target is nearly reached. Hence, ac-
curacy will be most important in the discrete aiming tasks and 
these are therefore likely to be performed at lower speed.
A second rationale for the present study was that there is a 
need to evaluate the long-term effects of BoNT-A. An earlier 
study showed that directly after BoNT-A the accuracy and 
speed of movements were reduced in KAT tasks (16), but it is 
not known what the long-term effects are on this type of tests. 
In the present study we are interested in the effect on speed and 
accuracy after a long period of PT/OT with (BTX+ group) or 
without (PT/OT group) additional BoNT-A. The present study 
took place over a period of 6 months therapy, with 3 months 
follow-up after the therapy period. A randomized design was 
used with 2 groups. 
The aims of the study were: (i) to evaluate whether spasticity 
and range of motion correlate with movement time and accuracy 
at baseline; (ii) to evaluate the effect of intensive therapy on move-
ment time and accuracy in aiming tasks compared with baseline; 
and (iii) to evaluate the additive effect of BoNT-A and intensive 
therapy on movement time and accuracy in aiming tasks.
METHODS
Participants
Twenty children with cerebral palsy (CP) participated in this study, 
age range 4–16 years, mean age 9.5 years. They were diagnosed with 
spastic hemiplegia according to the Hagberg classification (25) and were 
classified based on the severity of the hand function using the Zancolli 
classification (pattern of hand function impairment, pattern I, IIa, IIb) 
(26). Exclusion criteria were: children with a cognitive level below 
3 years, with Zancolli III and movement limitation of wrist or elbow 
extension of more than 30º. An overview of the baseline and follow-up 
characteristics of the participants is given in Table I. A specific PT/OT 
programme adapted to each Zancolli level was developed. The current 
data were collected in conjunction with the study of Speth et al. (17). 
The parents gave informed consent and the study was approved by the 
medical ethics committee of the Rehabilitation Foundation Limburg. 
Design
Ten pairs of children were formed after matching according to age 
and Zancolli level (I and II). A BTX+ group and PT/OT group were 
formed after random allocation within each pair. Randomization was 
performed by computer. Only one of the pairs had different Zancolli 
levels (I, II). Outcome measures were collected at baseline (2 weeks 
before BoNT-A), 2 weeks after BoNT-A, and at 3, 6 and 9 months after 
the start of therapy. The PT/OT group was tested in the same weeks as 
the BTX+ group. No children were lost to follow-up (Fig. 1).
Therapy programme and splinting
The specific therapy programme was standardized and task-oriented. 
Training of skills (27) and strength (28) was performed within task-
specific activities, based on the individual demands and specific goals 
of each child. A thermoplastic night splint was used to improve passive 
range of motion (PROM) – the elbow extended, a neutral forearm, 20º ex-
tension of the wrist and thumb in abduction. For the participants graded 
Zancolli IIB a cock-up splint (wrist in 20º extension) was made, which 
they wore during the day. The duration of the therapy was 30 minutes of 
physical and occupational therapy each, 3 times a week, over a period of 
6 months. The therapy was supervised by experienced therapists.
Injection technique and dosage
Botox® (Allergan, Irvine, USA) was used (dilution 5 U/0.1 ml). Dosage 
was 2–3 U/kg bodyweight in the upper arm, 1–2 U/kg bodyweight in 
Table I. Changes in Angle of Catch, Active Range of Motion, and Passive 
Range of Motion of the wrist and elbow, and Melbourne Assessment (MA) 











Angle of Catch wrist (°) 57.7 (21.1) 69.9* (17.5) 70.7 (15.6)
Angle of Catch elbow (°) 136.7 (36) 158.7* (29.8) 167.5 (21.7)
Active dorsal flexion wrist (°) –3.7 (37) 22.7* (31) 16.5 (34.1)
Active extension elbow (°) 165.5 (15.5) 172.5* (13.1) 175 (8.5)
Passive dorsal flexion wrist (°) 72.5 (12.4) 74.7 (12.9) 74.5 (14)
Passive extension elbow (°) 176.2 (13.1) 177.7 (7.8) 178.7 (5.8)
Melbourne Assessment (%) 64 (10) 67 (9.9) 66.6 (11.9)
p <  0.05.
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the forearm, with a maximum of 50 units at any one site, with an overall 
maximum dose of 400 U/kg total bodyweight (17). Predominantly the m. 
adductor pollicis (10 U), the m. flexor carpi ulnaris (2 × 20–2 × 40 U) and 
the m. pronator teres (30–50 U) were injected and less frequent injections 
were given in the m. flexor carpi radialis (30–2 × 30 U), m. biceps bra-
chialis (2 × 20–2 × 50 U), m. brachioradialis (40–2 × 40 U) and m. flexor 
pollicis brevis (5 U), as described in the study of Speth et al. (17). The 
number of units per total bodyweight ranged from 2.9 to 5.8 U.
Outcome measures
Experimental outcome measures. In the 3 KAT tasks, the children held a 
digital pen embedded in a custom-made puppet (length 7 cm, diameter 
2.5 cm) in their affected hand. They could directly see their movements. 
Movements were made on a digitizer (Wacom, type Cintiq 18sx, sample 
rate 206 Hz, KIKO software, Doetinchem, The Netherlands). This 
digitizer was also a SXGA full 24-bit colour LCD monitor and was 
placed directly in front of the participant (Fig. 2). The glass surface of 
the monitor made the shifting movement easy. 
Three tasks were performed, a discrete visually-guided tapping 
task (lift task), a discrete visually-guided shift task (shift task) and an 
alternating visually guided shift task (alternating task). Oasis software 
(KIKO software) was used to program the 3 tasks (29). Movements were 
made over a distance of 20 cm and to a target with the same diameter 
as the puppet (2.5 cm).
The goal for the children in these aiming tasks was to get the puppet 
in the target circle (2.5 cm diameter) while performing a substantial arm 
movement (20 cm). After putting the puppet on the digitizer in the start-
ing circle on the left side the investigator pressed the start button. After 
a random period (between 0.5 and 1.5 s) a tone sounded and the other 
target appeared on the right side of the digitizer, 20 cm from the target 
on the left side. This was the “go” signal for the child, who was then 
required to move as fast and as accurately as possible to the target.
In the lift task the puppet had to be lifted and land on the target 
that had appeared. In the shift task the puppet had to be shifted. If 
the puppet landed on the target and was kept stationary (if speed was 
below 0.2 cm/s) a new starting sound was given and the puppet had 
to be moved to the other side. The total number of movements was 
restricted to 10 per trial. 
In the alternating task a start signal was given and over a period of 20 
s the puppet had to be shifted between both targets as often as possible 
with the highest accuracy. After 20 seconds a stop signal was given. 
The tasks were presented in the same order to all the children; 
namely, lift, shift, and alternating task. This was done because random 
order led to too many mistakes in performance. After a practice session 
for all tasks the experiment began. 
Signal analysis. Spatial accuracy was calculated in 2 ways: first using 
the dichotomy between the correct and incorrect responses (Proportion 
Successful Movements; PSM); secondly, as the distance of the centre 
of the puppet to the centre of the target (End-point Spread; END, 
mm). Movement Time (MT, seconds) per segment was calculated as 
a temporal variable. The MT started when a puppet was lifted/shifted 
and ended when the speed of the puppet in the target dropped below 
0.2 cm/s in the target. The IP-E (bits/s) was calculated, expressing the 
relationship between movement speed and accuracy in goal-directed 
movements (37). In formula format the definition is: IP-E = a + b*Log2 
(2A/ ETW) /MT (where a and b are empirical constants, A = distance 
between targets, ETW = effective target width, and MT = movement 
time). The ETW is calculated as the distance between the centre of 
the target and the centre of the puppet. 
Outcome measures for spasticity and mobility. Spasticity was meas-
ured with the Ashworth Scale (AS) and the Stretch-Restricted Angle 
(SRA) for the extension of the wrist and elbow (30–31). Spasticity was 
measured in the supine position. The SRA was assessed by moving 
the wrist and elbow as fast as possible (within 1 second) through the 
whole range of motion (31). 
Mobility was registered by measuring the active and passive range 
of motion (AROM and PROM) of the wrist and elbow extension while 
the participant was in the sitting position. Standardized goniometry 
(MIE, Medical Research Ltd clinical goniometry) was used to measure 
SRA, AROM and PROM (32).
Manual ability of the affected hand was measured with the Mel-
bourne Unilateral Upper Limb Assessment, because of the reliabil-
ity and validity for unilateral upper limb function in children with 
spasticity in the studied age group (7). MA was scored from video 
recordings, after encoding and randomization (children and occasions 
of measurements). Trained movement scientists (double-blinded) 
scored the videos. 
The clinical outcome measures have been reported earlier (22) and 
were used in the study to evaluate whether spasticity, and range of 
motion showed a correlation with movement time and accuracy at 
baseline and after the end of therapy.
Statistics
KAT task outcome measures. The dependent variables PSM, END, 
MT and IP-E were evaluated by means of the General Linear Model 
(Polynomial), Repeated Measures design, with group (2) and session 
(5) as between-subject variables, and task (3) as within-subject vari-
able. Post-hoc analyses were used, if appropriate, to further analyse: (i) 
baseline and 6 months (to measure the effect of therapy); (ii) baseline 
and 9 months (to measure the long-term effect); and (iii) 6 vs. 9 months 
(to measure the lasting effect after the end of therapy).
Spearman’s rank correlation was calculated to examine whether the 
outcome measures, AROM, PROM, SRA and AS, correlated with MT, 
END, and IP-E at baseline and at the end of the therapy period. The 
alpha level was set at 0.05. 
χ2 statistics were used to look for differences between groups at 
baseline.
Fig. 2. Experimental set-up with a digitizer as colour LCD monitor. The 
tablet is placed directly in front of the participant. The digital pen is 
embedded in a “puppet” of 2.5 × 7 cm.
Fig 1. The CONSORT flow-chart
          The Consort E-Flowchart August 2005 
 








Assessed for eligibility  (n= 24) 
Excluded (n= 4) 
Not meeting inclusion criteria (n= 2) 
Refused to participate (n= 2) 
Other reasons (n= 0) 
Analyzed (n= 10) 
Excluded from analysis (n= 0) 
Lost to follow-up (n= 0) 
Discontinued intervention (n= 0) 
Allocated to intervention (n= 10) 
Received allocated intervention  
(n= 10) 
Did not receive allocated inter-
vention (n= 0) 
Lost to follow-up (n= 0) 
Discontinued intervention (n= 0) 
Allocated to intervention (n= 10) 
Received allocated intervention 
(n= 10) 
Did not receive allocated intervention 
(n= 0) 
Analyzed (n= 10) 
Excluded from analysis (n= 0) 
1.3   Allocation 
1.2   Analysis 
2.1   Follow-Up 
1.1   Enrollment 
Is it Randomized? 
Yes 
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RESULTS
All participants completed the therapy and the measurement 
programme. There was no loss to follow-up. There were no 
statistical differences between the groups at baseline. 
Outcome measures for spasticity, mobility and manual ability
The results of the clinical tests after the intervention have been 
described in a previous publication on the same group of par-
ticipants (22). Since these findings are essential to compare with 
the present experimental data the results are summarized briefly 
in Table I, showing the significant changes. In summary, meas-
ured over all children, AROM and SRA of the wrist increased 
and Ashworth scores decreased. For both groups combined, a 
significant increase in AROM and SRA of the wrist was found 
at the end of the therapy period. Furthermore, a significant de-
crease in Ashworth scores of the wrist and elbow were found at 
the end of the therapy period. The percentile scores of the MA 
did not show any significant improvement on any of the test 
occasions. Importantly, no significant differences were found 
between groups.
Experimental outcome measures
Overall. A significant main effect of task was found for all 
the outcome measures (MT F(2,36) = 8.07, p = 0.001; PSM 
F(2,36) = 2.6, p = 0.008; IP-E F(2,36) = 8.55, p = 0.001), indicat-
ing that the 3 tasks tested different elements of the aiming task. 
No main effect was found for session. However, a significant in-
teraction effect of task and session was shown for each outcome 
measure (MT F(8,144) = 14.47, p < 0.001; PSM F(8,144) = 23.28, 
p < 0.001; END F(8,144) = 6.25, p < 0.001; IP-E F(8,144) = 18.65, 
p < 0.001), indicating that session resulted in different effects 
on the underlying mechanisms measured with the tasks. Only 
significant interactions of task, session and group were found 
for MT (F(8,144) = 4.21, p = 0.04) and for IP-E (F(4,188) = 5.34, 
p = 0.03), indicating that the groups performed differently over 
time on the tasks related to MT and IP-E (Figs 3–6).
Movement time. As seen in Fig. 3 the PT/OT group showed 
very similar performance at the end of the therapy in the shift 
task (from 1.1 (0.07) to 1.2 s (0.09)), and in the alternating task 
(from 0.9 (0.12) to 0.95 s (0.1)). On the other hand, a minor 
decrease in MT was found in the lift task from 1.4 (0.09) to 1.2 
s (0.06), meaning that they moved slightly faster. The BTX+ 
group showed a small decrease both in the lift task (from 1.4 
(0.09) to 1.2 s (0.07)), and in the shift task (from 1.4 (0.1) 
to 1.3 s (0.1)), whereas a clear decrease in MT was found in 
the alternating task (from 1 (0.08) to 0.7 s (0.07)), indicating 
a positive influence of the added BoNT-A in fast alternating 
movement tasks. Post-hoc analysis of the period baseline and 
the end of the therapy showed a significant interaction of tasks 
by session by groups (F (2,36) = 3.76, p = 0.03). This is caused 
mainly by the larger difference in MT between both groups in 
the alternating task at the end of therapy, 
This effect was diminished 3 months after the end of therapy.
Fig. 3. Movement Time in all 3 kinematic aiming tasks (KAT). Measurement at baseline, after 2 weeks (short), at the end of the therapy period (end) 
and 3 months after the end of therapy (follow-up). Error bars are ± 1 standard error of mean. *Significant at post-hoc testing. BTX: intervention group 
with botulinum toxin, PT/ OT; intervention group without botulinum toxin.
 
---- ---- BTX+                _____ ______      PT/OT 
 
* 
Fig. 4. Proportion Successful Movements in all 3 kinematic aiming tasks (KAT). Measurement at baseline, after 2 weeks (short), at the end of the therapy 
period (end) and 3 months after the end of therapy (follow-up). Error bars are ± 1 standard error of mean. BTX: intervention group with botulinum 
toxin, PT/ OT; intervention group without botulinum toxin.
  
---- ---- BTX+                _____ ______      PT/OT 
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Accuracy (percentage successful movements (PSM) and end-
point spread (END)). Both PSM as END did not show effects 
of group, and there were no interactions with task or session. In 
Fig. 4 it is shown that at the end of therapy in the lift task both 
groups improved their PSM. In contrast, in the shift task they 
did not improve. In the alternating task both groups showed a 
decrease in PSM, indicating that in these fast movements the 
accuracy was not improved in either group. 
END. As illustrated in Fig. 5, the spread of end-points showed 
a non-significant small decrease in the lift and shift tasks 
for both groups at the end of therapy. In the alternating task 
both groups showed a non-significant small increase in END, 
indicating that neither group could improve their accuracy if 
speed is involved, despite intensive intervention. 
Index of Performance Effective. Both MT and END are essen-
tial elements of performance in the aiming tasks, and influence 
each other negatively. We therefore used the IP-E as a measure 
capturing the 2 elements and correcting for the speed accuracy 
trade-off (24). Analysis of the period baseline and the end of 
therapy showed a significant interaction of tasks by session 
by groups (F (2,36) = 2.85, p = 0.01). This is caused mainly 
by the difference in performance in the alternating task. As 
illustrated in Fig. 6 for the alternating task, a clear increase 
was found in IP-E for the BTX+ group, from 2.9 (0.2) to 3.6 
bits/s (0.4) and a small increase was found for the PT/OT group 
at the end of the therapy, from 2.9 (0.2) to 3.1 bits/s (0.3). In 
the lift task only a slight improvement in IP-E was seen for 
the PT/OT group at the end of therapy, from 1.8 (0.1) to 2.1 
bits/s (0.1), whereas the BTX+ group showed no differences 
(from 2.1 (0.1) to 2.1 bits/s (0.1)). In the shift task the PT/OT 
and BTX+ groups performed comparably and showed equal 
scores at baseline and at the end of therapy. 
Hence the only gain was seen in the alternating task and this 
gain was more beneficial for the BTX+ group. IP-E decreased 
after the end of therapy in the alternating task in both groups 
(to 3.1 bits/s (0.2) in the BTX+ group and to 2.8 bits/s (0.2) 
in the PT/OT group), indicating that 3 months after the end of 
therapy the gain in therapy was diminished.
Correlation between clinical and experimental outcome 
variables
As seen in Table II a significant correlation at baseline was 
present for AROM of the wrist with IP-E in the lift task (rho 
0.67) (p = 0.001). In all tasks AROM of the wrist had a significant 
negative correlation with the accuracy parameter END, most 
probably indicating that active wrist mobility is important for 
accurate task performance. At baseline there was a significant 
positive correlation of Ashworth score of the wrist with MT in 
the lift task (rho 0.49) (p = 0.02) and a negative correlation of 
Ashworth score with IP-E (rho –0.52) (p = 0.02) in the alternating 
task, indicating that if high flexor tone of the wrist is present, 
movements are slow and IP-E will be low in an accuracy task 
if either speed or lifting an object is important. 
Fig. 5. Endpoint Spread in all 3 kinematic aiming tasks (KAT). Measurement at baseline, after 2 weeks (short), at the end of the therapy period (end) 
and 3 months after the end of therapy (follow-up). Error bars are ± 1 standard error of mean. BTX: intervention group  with botulinum toxin, PT/ OT; 
intervention group without botulinum toxin.
 
---- ---- BTX+                _____ ______      PT/OT 
 
Fig. 6. Index of Performance Effective (IP-E) in all 3 kinematic aiming tasks (KAT). Measurement at baseline, after 2 weeks (short), at the end of the 
therapy period (end) and 3 months after the end of therapy (follow-up). Error bars are ± 1 standard error of mean. *Significant at post-hoc testing. BTX: 
intervention group with botulinum toxin, PT/ OT; intervention group without botulinum toxin.
 
---- ---- BTX+                _____ ______      PT/OT  
* 
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A significant negative correlation was found for MA with 
END in the shift task (rho –0.63) (p < 0.01) and with END in the 
alternating task (rho –0.65) (p < 0.001) and a significant posi-
tive correlation with IP-E in the lift task (rho 0.53) (p = 0.01), 
indicating that if the ability to perform movements accurately 
is high, MA scores will also be high.
DISCUSSION
Standardized therapy was performed in this randomized con-
trolled study (RCT) over a 6-month period. The standardized 
therapy was based on task-oriented training, strength training 
and the use of splints. Half of the group received additional 
BoNT-A. For both the PT/OT and BTX+ groups this resulted in 
a clinically relevant increase in AROM of the wrist and elbow. 
In addition the scores on the Ashworth Scale decreased. The 
decrease in spasticity and increase in AROM are mentioned in 
most of the studies in the 3 week period after BoNT-A, indicat-
ing a tone-reducing effect of BoNT-A (17–22). 
The crucial question is how these changes affect functional 
manual ability and whether it is possible to identify tasks in which 
such ability is improved. The present study shows that even when 
global assessments of manual ability fail to show improvement 
one can quantify improvement in very specific subtasks.
For the global assessment the MA test was used. Both 
groups showed a small non-significant increase in MA scores 
of 3 percentiles, which is less than the smallest detectable dif-
ference (8.9 percentile for the Melbourne Assessment) (33). 
This is in coherence with all review studies on BoNT-A and 
treatment of the upper limb, also showing no clear improve-
ment in functional clinical measures (19–21). Furthermore in 
a prospective longitudinal study of 2 years duration, Satila 
et al. (34) concluded that the reduction in muscle tone after 
BoNT-A treatment did not translate into better gripping or 
quality of fine motor functions (Melbourne Assessment) of 
the affected hand. 
The MA assesses many aspects of motor control, however, and it 
is possible that more detailed analysis is needed to reveal function-
ally important changes in manual ability. To identify such subtle 
changes a battery of 3 simple tests was used and performance was 
evaluated in terms of parameters of speed (MT), accuracy (PSM 
and END) and their combination (IP-E). In the alternating task 
the IP-E of the PT/OT group showed a small increase at the end 
of the therapy period and the BTX+ group improved significantly 
more. This increase was related to a significant decrease in MT 
while accuracy measures were unchanged (or even showed a 
non-significant decrease). Hence the PT/OT group moved more 
slowly and somewhat more accurately. This resulted in a benefit 
to the BTX+ group regarding IP-E. In the alternating task a fast 
alternating contraction and release of forearm muscles (wrist and 
elbow) is needed to perform this task adequately (35). The children 
have to master the degrees of freedom of the musculoskeletal 
system to control these fast alternating goal-directed movements 
(36–37). The tone-reducing effect of BoNT-A seems to facilitate 
the programming and execution of these movements with higher 
speed, resulting in improved IP-E for the BTX+ group. 
While the changes in the alternating task were the only sig-
nificant ones between groups, it is worthwhile considering some 
smaller tendencies seen in the other tasks. In this study we found 
the greatest increase in accuracy (expressed in PSM and END) 
in the lift task for both groups and a very small increase in the 
shift task when performance at end therapy was compared with 
baseline. There are several possible explanations for these positive 
findings. First, in the task-oriented therapy, mainly grip and lift 
tasks are practised, so they improved on what was trained (lift). 
Secondly, the selective improvement in the lift task may be related 
to the lift task being easier than the shift phase because homing-in 
is easier. In the shift task, the homing-in has to be controlled by 
slowing down gradually while this is not the case for the lift task 
where deceleration is relatively easy because of the impact on the 
surface at landing (acting to break the movement).
Study limitations
The study did not include either a control group without intensive 
therapy or a placebo group, thus we have to be cautious when 
generalizing our conclusions with regard to usual or no care.
Conclusion
We can conclude that intensive functional therapy with and 
without BoNT-A decreased spasticity and increased AROM 
Table II. Correlation of Movement Time (MT), Proportion Successful Movements (PSM), Endpoint Spread (END) and Index of Performance Effective 
(IP-E) with the clinical measures (AOC, Active Range of Motion, Passive Range of Motion, Ashworth Score (AS) and Melbourne Assessment) at 
baseline. Only significant correlations are presented. (Alpha was set at 0.05)
MT PSM END IP-E
Lift task
Active dorsal flexion wrist (°) –0.46 (0.02) –0.89 (0.00) 0.67 (0.001)
Ashworth score wrist 0.49 (0.02) –0.52 (0.02)
Melbourne Assessment (%) 0.53 (0.01)
Shift task
Active dorsal flexion wrist (°) –0.68 (0.00)
Ashworth score elbow 0.51 (0.01)
Melbourne Assessment (%) –0.63 (0.00)
Alternating task
Active dorsal flexion wrist (°) –0.81 (0.000)
Ashworth score wrist 0.58 (0.007) –0.58 (0.006)
Melbourne Assessment (%) –0.65 (0.00)
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of the wrist for both groups, with a slight non-significant 
benefit for the BTX+ group. Kinematic outcome measures 
show a larger and significant benefit for the BTX+ group 
for speed and performance in the alternating tasks. This in-
crease is based on the gain in movement speed but relative 
loss of accuracy. In contrast, performance in the alternating 
task for the PT/OT group did not show this benefit. More 
generally, it can be concluded that adequate AROM of the 
wrist is required successfully to perform discrete movement 
tasks, while a decrease in spasticity is needed to perform fast 
alternating tasks. 
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